Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrecizumab in early septic shock with elevated bio-ADM
NL-OMON48885Phase 2Active, not recruiting
- Sponsor
- Adrenomed AG
- Start
- Mar 2018
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adrecizumab in septic shock and sepsis, sponsored by Adrenomed AG. Primary endpoints: Mortality, Interruption of infusion and 1 more. Started Mar 2018; status: active, not recruiting.
02
Drugs
adrecizumab
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on NL-OMON48885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48885.